BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31101682)

  • 1. Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial.
    Minotti G; Menna P; Calabrese V; Greco C; Armento G; Annibali O; Marchesi F; Salvatorelli E; Reggiardo G
    J Pharmacol Exp Ther; 2019 Aug; 370(2):197-205. PubMed ID: 31101682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of Cardio-Oncology: Chronotropic and Lusitropic Effects of B-Type Natriuretic Peptide in Cancer Patients with Early Diastolic Dysfunction Induced by Anthracycline or Nonanthracycline Chemotherapy.
    Menna P; Calabrese V; Armento G; Annibali O; Greco C; Salvatorelli E; Marchesi F; Reggiardo G; Minotti G
    J Pharmacol Exp Ther; 2018 Jul; 366(1):158-168. PubMed ID: 29720563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs.
    Minotti G
    J Pharmacol Exp Ther; 2013 Sep; 346(3):343-9. PubMed ID: 23818683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Endogenous Lusitropic and Chronotropic Agent, B-Type Natriuretic Peptide, Limits Cardiac Troponin Release in Cancer Patients with an Early Impairment of Myocardial Relaxation Induced by Anthracyclines.
    Menna P; Salvatorelli E; Armento G; Annibali O; Greco C; Marchesi F; Calabrese V; Reggiardo G; Minotti G
    J Pharmacol Exp Ther; 2018 Dec; 367(3):518-527. PubMed ID: 30275150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac Anthracycline Accumulation and B-Type Natriuretic Peptide to Define Risk and Predictors of Cancer Treatment-Related Early Diastolic Dysfunction.
    Minotti G; Salvatorelli E; Reggiardo G; Mangiacapra F; Camilli M; Menna P
    J Pharmacol Exp Ther; 2022 Jun; 381(3):266-273. PubMed ID: 35332076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Early or Delayed Diastolic Dysfunction After Anthracycline-Based or Nonanthracycline Chemotherapy: A Pharmacological Appraisal.
    Minotti G; Menna P; Camilli M; Salvatorelli E; Reggiardo G
    J Pharmacol Exp Ther; 2021 Feb; 376(2):231-239. PubMed ID: 33168644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study.
    Calabrese V; Menna P; Annibali O; Armento G; Carpino A; Cerchiara E; Greco C; Marchesi F; Spallarossa P; Toglia G; Reggiardo G; Minotti G;
    Chemotherapy; 2018; 63(2):55-63. PubMed ID: 29428939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy.
    Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Clarke JL; Thomas L
    Eur Heart J Cardiovasc Imaging; 2013 Mar; 14(3):228-34. PubMed ID: 22782955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranolazine in treatment of stable angina in woman with atrial fibrillation and intermittent left bundle branch block - a case report.
    Yuriivna Osovska N; Vitaliivna Kuzminova N
    Pol Merkur Lekarski; 2016 Dec; 41(246):287-292. PubMed ID: 28024133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology.
    Minotti G; Menna P; Camilli M; Salvatorelli E; Levi R
    Adv Pharmacol; 2022; 94():365-409. PubMed ID: 35659376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study.
    Boyd A; Stoodley P; Richards D; Hui R; Harnett P; Vo K; Marwick T; Thomas L
    PLoS One; 2017; 12(4):e0175544. PubMed ID: 28407011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Anti-Anginal Drugs: Ranolazine.
    Cavallino C; Facchini M; Veia A; Bacchni S; Rosso R; Rognoni A; Rametta F; Lupi A; Bongo AS
    Cardiovasc Hematol Agents Med Chem; 2015; 13(1):14-20. PubMed ID: 25544118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated B-type natriuretic peptide levels after anthracycline administration.
    Suzuki T; Hayashi D; Yamazaki T; Mizuno T; Kanda Y; Komuro I; Kurabayashi M; Yamaoki K; Mitani K; Hirai H; Nagai R; Yazaki Y
    Am Heart J; 1998 Aug; 136(2):362-3. PubMed ID: 9704703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ranolazine in a model of doxorubicin-induced left ventricle diastolic dysfunction.
    Cappetta D; Esposito G; Coppini R; Piegari E; Russo R; Ciuffreda LP; Rivellino A; Santini L; Rafaniello C; Scavone C; Rossi F; Berrino L; Urbanek K; De Angelis A
    Br J Pharmacol; 2017 Nov; 174(21):3696-3712. PubMed ID: 28320043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioprotective effect of Platycodon grandiflorum in patients with early breast cancer receiving anthracycline-based chemotherapy: study protocol for a randomized controlled trial.
    Hao W; Liu S; Qin Y; Sun C; Chen L; Wu C; Bao Y
    Trials; 2017 Aug; 18(1):386. PubMed ID: 28830541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
    Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
    J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function.
    Shah NR; Cheezum MK; Veeranna V; Horgan SJ; Taqueti VR; Murthy VL; Foster C; Hainer J; Daniels KM; Rivero J; Shah AM; Stone PH; Morrow DA; Steigner ML; Dorbala S; Blankstein R; Di Carli MF
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28473401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study.
    Maier LS; Layug B; Karwatowska-Prokopczuk E; Belardinelli L; Lee S; Sander J; Lang C; Wachter R; Edelmann F; Hasenfuss G; Jacobshagen C
    JACC Heart Fail; 2013 Apr; 1(2):115-22. PubMed ID: 24621836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults.
    Dodos F; Halbsguth T; Erdmann E; Hoppe UC
    Clin Res Cardiol; 2008 May; 97(5):318-26. PubMed ID: 18193371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
    Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
    Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.